Terrence G. Schneider, VP of Supply Chain at DIGI INTERNATIONAL INC (NASDAQ:DGII), sold 14,182 shares of common stock for $930,473 after exercising employee stock options. The shares were sold at a weighted average price of $65.6095, following their acquisition at an exercise price of $16.75 per share. This transaction occurred as DGII stock trades near its 52-week high, with the company recently reporting strong financial results and introducing a new compliance solution.

AMERIPRISE FINANCIAL INC has significantly reduced its stake in Quanterix Corp (QTRX) by 80.18%, selling 4,005,849 shares at $3.13 each. This move leaves the investment firm with 990,224 shares of Quanterix, representing 2.10% of its portfolio. The transaction reflects a strategic reallocation by AMERIPRISE FINANCIAL, possibly due to Quanterix's underperformance, as the stock has since declined by 8.15% and has a low GF Score of 67/100, indicating poor future performance and potential as a value trap despite being significantly undervalued.

CoStar Group (CSGP) is under scrutiny following its removal from the Nasdaq-100 and a reported slowdown in U.S. multifamily construction, contributing to a significant drop in its share price. Despite being framed as undervalued by a narrative fair value of $49.32 and a SWS DCF model value of $61.52, the company's P/S ratio remains higher than peers and the industry average. Investors are left to weigh whether current pricing reflects temporary pressure or indicates a premium that still needs to be justified by future growth and successful integration of new initiatives like Homes.com.

Kahn Swick & Foti, LLC (KSF) has notified investors of a class action securities lawsuit against LKQ Corporation (NASDAQ: LKQ). The lawsuit alleges securities fraud between February 27, 2023, and July 23, 2025, stemming from misrepresentations regarding LKQ's acquisition and integration of FinishMaster. Investors who suffered losses have until June 22, 2026, to apply for lead plaintiff status.

This article highlights Gina Beredo, Executive Vice President, General Counsel, and Secretary at Nordson Corp., as one of the "Women of Note 2019" by Crain's Cleveland Business. The brief entry mentions her role and the recognition she received in 2019.

Jin Zhao, President of Diodes Asia, sold 2,760 shares of Diodes Inc (DIOD) on May 12, 2026, reducing his holdings to 32,100 shares. This transaction is part of a trend of 18 insider sells and no buys over the past year for the company. Diodes Inc is currently trading at $102.36, indicating it is significantly overvalued with a price-to-GF-Value ratio of 1.54 compared to its intrinsic GF Value of $66.37.

Brett Whitmire, CFO of a Diodes Inc (DIOD) subsidiary, sold 16,556 shares of the company on May 13, 2026. This transaction follows a total of 18 insider sales and no insider buys at Diodes Inc over the past year. The stock is currently trading at $103.34, which is significantly above its GF Value of $66.37, indicating it is overvalued.

Marriott International director Grant Reid was granted 670 deferred Class A shares at a price of $0.00 per share, increasing his direct holdings to 3,518 shares. This award is part of a director deferred stock compensation plan and will vest daily pro-rata over twelve months, with distribution occurring after his service as a Board member ends. This transaction was a grant, not an open-market purchase, and is detailed in a recent SEC Form 4 filing.

Valero Energy Corporation (VLO) has significantly outperformed the broader market and the energy sector over the past year, with its stock rallying 80.9%. The company recently reported Q1 results that exceeded analyst expectations, showing a 7% year-over-year revenue growth and higher-than-anticipated EPS. Wall Street analysts maintain a "Moderate Buy" consensus rating for VLO, with a mean price target suggesting a modest upside from current levels, and some analysts predicting a potential upside of over 22%.

The European Commission has approved Pfizer's HYMPAVZI (marstacimab) to expand its indication for adults and adolescents aged 12 and older with hemophilia A or B who have inhibitors. This once-weekly subcutaneous treatment demonstrated superior bleed reduction compared to on-demand therapy in Phase 3 trials and is the only medicine approved in the EU for both hemophilia A and B with or without inhibitors. The approval provides a new critical treatment option for patients whose traditional factor replacement therapies are ineffective due to inhibitor development.